Product Briefs: IPF Breakthroughs, Bigger Labels For Velcade And Lymphoseek, Acura Appeal Denied
Executive Summary
Roche’s Esbriet and Boehringer’s Ofev become the first drugs approved by FDA for idiopathic pulmonary fibrosis; Velcade approved for first-line mantle cell lymphoma; Lymphoseek cleared for solid tumors; Acura mulls next steps after losing appeal on abuse-deterrent claim for Vycavert.